Panitumumab

Panitumumab is a type of medicine called an antibody. It works by blocking a protein called EGFR that helps cancer cells grow. This medicine is used to treat a specific type of cancer called metastatic colorectal cancer. It helps stop the cancer from spreading.

Brand names:Vectibix
Medication

What people taking Panitumumab report

Every report comes from a Lived member, sent anonymously.

Have you tried Panitumumab for Colorectal Cancer?

NameHow it went

About Panitumumab

What It's For

Panitumumab, sold as Vectibix, is a targeted cancer medicine used for colorectal cancer that has spread beyond the colon or rectum (metastatic colorectal cancer) in adults. It is a monoclonal antibody, a lab-made protein designed to attach to one specific target, rather than traditional chemotherapy. Whether it can help depends on the genetics of the tumor, so the tumor tissue is tested before it is ever offered. The key genes are KRAS and NRAS, together called RAS. When neither gene is mutated (described as RAS wild-type), panitumumab is approved in two ways: as part of first treatment for metastatic disease, combined with FOLFOX chemotherapy (a regimen of fluorouracil, leucovorin and oxaliplatin), or on its own once the cancer has grown despite the standard chemotherapy drugs fluorouracil, oxaliplatin and irinotecan. There is one exception for RAS-mutant cancer. For tumors with a particular mutation called KRAS G12C, panitumumab is approved together with sotorasib (Lumakras), a pill that targets that mutation, after the standard chemotherapy drugs have been tried. For other RAS mutations, or when RAS status is unknown, panitumumab is not used: it brings the side effects without benefit, and with FOLFOX it was linked to shorter survival. Cetuximab (Erbitux) is a similar antibody against the same target, and in a head-to-head trial of previously treated cancer the two gave comparable survival. Oncologists also often consider which side of the colon the cancer began in. In a large trial of RAS wild-type cancer that started on the left side, adding panitumumab to first-line chemotherapy led to longer survival than adding bevacizumab (Avastin), a different targeted drug.

How It Works

Many cells carry a receptor on their surface called EGFR (epidermal growth factor receptor). When growth signals lock onto it, EGFR switches on a chain of messages inside the cell that tell it to grow and divide. Many colorectal cancers rely on this pathway. Panitumumab binds to EGFR and blocks those growth signals from attaching, which can slow the cancer's growth or shrink tumors. It does not work when a RAS gene is mutated in the usual way, because RAS sits further down the same chain: a mutated RAS protein stays switched on by itself, so blocking the receptor above it makes little difference. With KRAS G12C, sotorasib switches off the faulty RAS protein while panitumumab blocks the receptor, attacking the pathway at two points. EGFR is also active in normal skin, hair follicles and the lining of the gut, which is why rash, nail problems and diarrhea are such typical side effects.

Dosage & Administration

Panitumumab is given as an intravenous (IV) infusion, a slow drip into a vein, at a cancer center or infusion clinic. A typical schedule is once every two weeks, with each infusion lasting about 60 minutes, or about 90 minutes for larger doses. The dose is based on body weight. When it is combined with FOLFOX, panitumumab is usually given first on the same day as the chemotherapy. When it is combined with sotorasib, the sotorasib pill is started before the first infusion, and panitumumab is paused or stopped whenever sotorasib is paused or stopped. Treatment usually continues for as long as it is controlling the cancer and side effects remain manageable. If a skin reaction becomes severe, the care team may skip one or two doses and then restart, sometimes at a lower dose.

Side Effects

Skin reactions are the hallmark side effect and carry the drug's boxed warning, the most prominent caution the US Food and Drug Administration (FDA) puts on a label. Nine in ten people treated with panitumumab alone develop some skin change, and about one in seven has a severe reaction. The most typical form is an acne-like rash, along with itching, redness, peeling, dry or cracked skin, and painful swelling or infection around the fingernails and toenails (paronychia). Sunlight makes the rash worse, so sunscreen, hats and limited sun exposure are advised during treatment and for two months afterward. Fatigue, nausea, diarrhea and mouth sores are also common, especially with chemotherapy. Low magnesium is frequent and is usually found on routine blood tests. Some reactions need prompt contact with the care team: skin that becomes very painful, hot, blistered or peeling, or a rash with fever, since serious skin infections have occurred; severe or ongoing diarrhea or signs of dehydration, which can lead to kidney damage; any eye problems or changes in vision, since serious inflammation of the cornea (the clear front of the eye) has occurred; and a new or worsening cough, wheezing or shortness of breath, which can rarely signal lung inflammation. Reactions during the infusion, such as fever, chills, trouble breathing or a drop in blood pressure, are uncommon and are handled by the infusion staff, who slow or stop the drip.

Interactions & Warnings

Panitumumab has no formal contraindications and few direct drug interactions, but how it is combined matters. Adding it to bevacizumab plus chemotherapy led to shorter survival and more severe side effects in a trial, so the two antibodies are not used together. Panitumumab can harm a developing baby. People who could become pregnant should use effective birth control during treatment and for at least two months after the last dose, and tell the care team right away about a known or possible pregnancy. Breastfeeding is not recommended during treatment and for two months afterward. The drug may also reduce fertility in women, which is worth raising before treatment starts if future pregnancy matters. People who already have lung scarring or inflammation of the lungs need a careful discussion of whether the benefit outweighs the risk.

What to Expect

Treatment follows a two-week rhythm of infusion visits, usually with blood tests. Magnesium, calcium and potassium are checked before starting, during treatment and for up to eight weeks after it ends, and supplements or IV replacement are given when levels drop. Regular scans show whether the cancer is shrinking, stable or growing, and that guides whether treatment continues. For many people the skin reaction is the most noticeable part of daily life on this drug, and managing it is an ongoing part of care alongside sun protection. For metastatic colorectal cancer, panitumumab is generally aimed at controlling the disease and extending life rather than curing it, although in some people tumors shrink enough that surgery to remove them becomes possible. Responses vary widely, and when the cancer eventually grows again, other treatments are usually available.

Questions to Ask Your Doctor

  1. 1.Has my tumor been tested for KRAS, NRAS and other markers, and what do the results mean for using panitumumab?
  2. 2.Why panitumumab rather than cetuximab or bevacizumab for my cancer, and does the side of the colon where it started matter?
  3. 3.What is the goal of this treatment for me, and how will we know whether it is working?
  4. 4.How can I prevent or manage the rash and nail problems, and which skin changes should I report right away?
  5. 5.How often will my magnesium and other blood levels be checked, and what birth control or fertility planning do I need?

Last reviewed • Oct 2026

Educational content, not medical advice.